AstraZeneca (LON:AZN) received a GBX 8,500 ($111.81) target price from equities research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 15.87% from the stock’s previous close.

A number of other research firms have also weighed in on AZN. Deutsche Bank reissued a “buy” rating and set a GBX 8,400 ($110.50) price target on shares of AstraZeneca in a research report on Tuesday, January 28th. Kepler Capital Markets raised their price target on shares of AstraZeneca from GBX 7,700 ($101.29) to GBX 8,000 ($105.24) and gave the company a “buy” rating in a research report on Tuesday, October 29th. Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca in a research report on Thursday, December 19th. Barclays raised their price target on shares of AstraZeneca from GBX 8,300 ($109.18) to GBX 8,500 ($111.81) and gave the company an “overweight” rating in a research report on Thursday, January 16th. Finally, Credit Suisse Group raised their price target on shares of AstraZeneca from GBX 8,200 ($107.87) to GBX 8,500 ($111.81) and gave the company an “outperform” rating in a research report on Thursday, January 16th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of GBX 7,912.14 ($104.08).

AZN opened at GBX 7,336 ($96.50) on Friday. The company has a debt-to-equity ratio of 148.59, a current ratio of 0.92 and a quick ratio of 0.70. The company’s 50-day moving average is GBX 7,668.20 and its 200 day moving average is GBX 7,328.85. AstraZeneca has a fifty-two week low of GBX 109.51 ($1.44) and a fifty-two week high of GBX 8,227.88 ($108.23). The firm has a market capitalization of $100.07 billion and a P/E ratio of 46.02.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: What is a Buy-Side Analyst?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.